Although the relief of systemic insulin resistance was not observed in the obesity treated with PDE5 inhibitor [6], recent animal studies and clinic trails have highlighted a possibility that PDE5 inhibition contributes to the improvement of insulin resistance in the subjects with diabetes [7–9]. This evidence concerns the gene PDE5A and obesity due to melanocortin 4 receptor deficiency.